Efficacy of the treatment of infectious diarrhoea with non-absorbable rifamycin SV formulated as MMX modified release tablet vs. rifaximin

ISSN: 2211-3533 (Online)
ISSN: 2211-3525 (Print)


Volume 12, 2 Issues, 2014


Download PDF Flyer




Anti-Infective Agents

Formerly: Anti-Infective Agents in Medicinal Chemistry

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Efficacy of the treatment of infectious diarrhoea with non-absorbable rifamycin SV formulated as MMX modified release tablet vs. rifaximin

Author(s): A. F. D. Di Stefano, D. Binelli, W. Labuschagne, M. Mojapelo, E. van der Walt, S. Patel and L. Moro


Abstract

Background: The non absorbable antibiotic rifamycin SV newly formulated as modified colonic release MMX tablets was preliminarily investigated. Methods: In a multi-centre, double-blind, double-dummy, randomised, parallel-group study, efficacy and safety of the 200 mg tablets were investigated vs. rifaximin 200 mg tablets in infectious diarrhoea. Results: 22 rifamycin SV recipients (47.8%) were successes, whilst 24 (52.5%) discontinued. In the reference group 27 (50.9%) were successes, whilst 26 (49.1%) discontinued. The median time to last unformed stool was 67.5 h after rifamycin SV and 65.5 h after rifaximin. Conclusions: The efficacy of the new tablets was not significantly different from that of rifaximin administered 4 times a day for 3 days. The treatments did not differ in rate or frequency of therapeutic success. Isolates of Campylobacter jejuni and lari, Escherichia coli, Anaerobiospirillum, Salmonella enteritidis and Shigella flexneri found at pre-treatment were not retrievable after rifamycin SV.


Purchase Online Rights and Permissions

  
  



Article Details

Volume: 11
First Page: 1
Page Count: 1
DOI: 10.2174/22113525113119990110
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science